Close Menu

NEW YORK – NanoString Technologies reported after the close of the market on Thursday that its first quarter revenues shrank 4 percent year over year.

For the three months ended March 31, total revenues were $26.6 million compared with $27.7 million in the prior-year period, exceeding the average Wall Street estimate of $25.4 million.

The firm reported product and service revenue of $24.5 million for the quarter, a 15 percent year-over-year growth from $21.4 in Q1 2019.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Russia says its candidate SARS-CoV-2 vaccine has a very high efficacy rate in an initial analysis of clinical trial data, according to the Financial Times.

Wired reports on a microbial analysis of sketches drawn by Leonardo DaVinci.

A new survey explores coronavirus vaccine hesitancy among Black and Latino individuals, the Washington Post reports.

In Nucleic Acids Research this week: the Aging Atlas database, a database of human metagenome-related metadata, and more.